The very best case scenario is MHRA is waiting on more data to eventually green light L for a specific tiny subset of patients that will somehow get the NICE nod. But it’ll mean little to investors. Advent is the key to ever getting ROI so you should all focus on that.
Market Data 
Markets 
AI
